Chemomab Therapeutics Ltd.

Develops antibody drugs neutralizing CCL24 for severe fibro-inflammatory diseases.

CMMB | NDAQ

Overview

Corporate Details

ISIN(s):: US16385C1045 (+1 more)
LEI:
Country:: United States of America
Address:: KIRYAT ATIDIM, BUILDING 7, 6158002 TEL AVIV
Website:: https://www.chemomab.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Chemomab Therapeutics Ltd. is a clinical-stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet medical needs. The company's approach is centered on its discovery of the soluble protein CCL24 as a key driver of the vicious cycle of fibrosis and inflammation. Its lead product candidate, nebokitug (CM-101), is a first-in-class, dual-activity monoclonal antibody designed to bind to and neutralize CCL24. Nebokitug has demonstrated disease-modifying potential and a favorable safety profile in multiple clinical trials for severe fibrotic diseases. Following positive Phase 2 data, Chemomab is preparing for a potential Phase 3 trial in primary sclerosing cholangitis (PSC), for which nebokitug has received FDA Fast Track and Orphan Drug designations.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Chemomab Therapeutics Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Chemomab Therapeutics Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Chemomab Therapeutics Ltd. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Eevia Health Plc Manufactures validated polyphenol extracts from Arctic plants for the supplement & food industries.	Finland	EEVIA
Egetis Therapeutics Develops and commercializes drugs for serious rare diseases with unmet medical needs.	Sweden	EGTX
EIKEN CHEMICAL CO.,LTD. Manufacturer of clinical diagnostics, specializing in FIT systems for cancer and microbiological tests.	Japan	4549
Eisai Co., Ltd. A global, research-based pharmaceutical firm that develops and markets prescription and OTC drugs.	Japan	4523
Elanco Animal Health Inc Develops medicines, vaccines, and services to treat and prevent disease in pets and farm animals.	United States of America	ELAN
Eledon Pharmaceuticals, Inc. Develops immunomodulatory therapies to prevent organ rejection in transplant patients.	United States of America	ELDN
Elicera Therapeutics AB Develops CAR T-cell & oncolytic virus therapies for cancer, enhanced by its iTANK platform.	Sweden	ELIC
ELI LILLY & Co Pharma leader developing medicines for diabetes, obesity, oncology, and neuroscience.	United States of America	LLY
Ellen AB Develops research-based probiotic and prebiotic products for women's intimate health and pH balance.	Sweden	ELN
ELUTIA INC. Develops drug-eluting biologics to reduce complications from medical implants.	United States of America	ELUT